-- Entropy Neurodynamics (ASX:ENP) filed a US provisional patent application based on clinical insights from the results of its phase 2a study of TRP-8802, or oral psilocybin, in patients with treatment-resistant, irritable bowel syndrome (IBS), according to a Tuesday Australian bourse filing.
The filing is in addition to its existing international patent application related to psychedelic-assisted therapy for disorders of gut-brain interaction, which was filed under the Patent Cooperation Treaty on Jan. 3, 2024.
The results highlighted a 75% response rate in treatment-resistant IBS patients, which the firm noted was the strongest clinical signal ever reported in IBS drug development.
Its shares fell 5% in recent trading on Tuesday.